NV-AQARA
8.1.2024 18:01:32 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, is thrilled to announce its participation in CES 2024. At the event, Aqara will showcase its latest innovations, including the new Border Router Plug and Smart Lock U300, as well as other advanced smart home solutions and prototypes at its booth in the Venetian Expo (#53513).
Aqara is an early advocate of the industry-unifying Matter standard and is committed to delivering seamless smart home experiences for users. The Border Router Plug and Smart Lock U300 will be Thread-capable, which will add to Aqara's growing number of native Matter products, making Aqara devices more interoperable. These two new products previewed at CES are expected to become available for order in the coming months.
Border Router Plug
The Aqara Border Router Plug represents an innovative advancement in smart plug and is among the first smart plugs announced to incorporate Thread Border Router capabilities. Equipped with Thread and dual-band Wi-Fi, this plug enables Matter controllers without Thread capability to manage Thread devices, allowing seamless integration of Thread devices into smart home systems without needing a new Matter controller.
This plug is energy-efficient, particularly in Thread-only mode, which reduces idle consumption while extending the mesh Thread network by routing the data packets. It is also energy-conscious, providing real-time and historical data on home energy consumption, enabling users to automate their electrical devices to reduce energy waste. Additionally, the Border Router Plug can sense the on/off status of the connected appliance and trigger Aqara Home automations accordingly. For example, users can have the curtains close automatically when the TV is on to eliminate potential sun glare.
The Aqara Border Router Plug utilizes an NXP® Semiconductors' secure wireless MCU. As part of the ongoing collaboration between Aqara and NXP Semiconductors, the Border Router Plug will also be featured in NXP's Smart Home Experience showcase during CES 2024, along with the NXP-powered Aqara Door and Window Sensor P2.
Smart Lock U300
The Aqara Smart Lock U300 is one of the first smart lever locks announced to feature Matter and Thread compatibility, and offers unprecedented interoperability with various smart home platforms. This versatility is coupled with an extended battery life of up to 8 months and enhanced local control, which improves responsiveness, privacy and security.
Designed for both indoor and outdoor use, the U300 replaces the traditional US lever or knob on single-bore doors and is ideal for including side entries, garage entries, home offices, basements and storage rooms. It enables a key-free lifestyle with multiple access options, including fingerprints, PIN codes, NFC, or voice assistants. Homeowners can control the lock remotely, grant temporary access to guests, and receive real-time notifications of who comes and goes - all from a smartphone.
Aqara Home App Update
At CES 2024, Aqara will also showcase Home Copilot, the new chatbot interface for the Aqara Home app, which is powered by Gen-AI. Home Copilot is designed to enhance user experiences by utilizing ambient intelligence, which helps convert real-time data and insights into actions. Ultimately, Home Copilot will be able to analyze the usage patterns in an Aqara home and proactively suggest customized automations. It will also understand natural language and configure automations per user requests. Users can automate their homes via simple voice and text instructions, which makes smart home even more intuitive and easy to use.
Initially, Home Copilot will enable Aqara Insights, a daily, weekly and monthly smart home reports for users, and provide tailored plans for energy-saving automation. It will support natural language queries for Aqara devices and automations and offer proactive assistance with device setup and troubleshooting. Home Copilot will also spearhead the AI-powered customer support interface for Aqara users in over 10 languages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108777203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom